Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
The source filing: Spyre Therapeutics, Inc.’s 10-K, filed February 19, 2026. Open the filing →
- Filed
- Feb 19, 2026, 4:01 PM EST
- Fiscal year
- FY2025
- Accession
- 0001636282-26-000020
FAQ
- What is Spyre Therapeutics, Inc.'s EBITDA?
- Spyre Therapeutics, Inc. (SYRE) reported EBITDA of -$57.17M in Q4 2025.
- How has Spyre Therapeutics, Inc.'s EBITDA changed year-over-year?
- Spyre Therapeutics, Inc.'s EBITDA increased by 6.7% year-over-year, from -$61.25M to -$57.17M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s EBITDA?
- Over 3 years (2021 to 2025), Spyre Therapeutics, Inc.'s EBITDA has grown at a 48.4% compound annual growth rate (CAGR), from -$64.07M to -$209.56M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Spyre Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude